- Home
- PCVX vs EXAS Comparison
PCVX vs EXAS Comparison
Compare PCVX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- EXAS
- Stock Information
- Founded
- PCVX 2013
- EXAS 1995
- Country
- PCVX United States
- EXAS United States
- Employees
- PCVX N/A
- EXAS N/A
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- EXAS Medical Specialities
- Sector
- PCVX Health Care
- EXAS Health Care
- Exchange
- PCVX Nasdaq
- EXAS Nasdaq
- Market Cap
- PCVX 13.2B
- EXAS 12.3B
- IPO Year
- PCVX 2020
- EXAS N/A
- Fundamental
- Price
- PCVX $86.51
- EXAS $49.33
- Analyst Decision
- PCVX Strong Buy
- EXAS Strong Buy
- Analyst Count
- PCVX 7
- EXAS 17
- Target Price
- PCVX $147.50
- EXAS $73.07
- AVG Volume (30 Days)
- PCVX 1.4M
- EXAS 3.3M
- Earning Date
- PCVX 11-05-2024
- EXAS 11-05-2024
- Dividend Yield
- PCVX N/A
- EXAS N/A
- EPS Growth
- PCVX N/A
- EXAS N/A
- EPS
- PCVX N/A
- EXAS N/A
- Revenue
- PCVX N/A
- EXAS $2,692,328,000.00
- Revenue This Year
- PCVX N/A
- EXAS $12.41
- Revenue Next Year
- PCVX N/A
- EXAS $11.64
- P/E Ratio
- PCVX N/A
- EXAS N/A
- Revenue Growth
- PCVX N/A
- EXAS 11.91
- 52 Week Low
- PCVX $48.24
- EXAS $40.62
- 52 Week High
- PCVX $121.06
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- PCVX 23.31
- EXAS 22.62
- Support Level
- PCVX $101.87
- EXAS $48.02
- Resistance Level
- PCVX $107.31
- EXAS $52.32
- Average True Range (ATR)
- PCVX 5.82
- EXAS 2.86
- MACD
- PCVX -2.04
- EXAS -1.89
- Stochastic Oscillator
- PCVX 3.58
- EXAS 5.28
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.